echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The CTLA-4, PD-1 track is crowded, and the development of the next generation of tumor immunotherapy is a new target for drug companies

    The CTLA-4, PD-1 track is crowded, and the development of the next generation of tumor immunotherapy is a new target for drug companies

    • Last Update: 2022-05-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Tumor immunotherapy refers to a treatment method to control and eliminate tumors by restarting and maintaining the tumor-immune cycle and restoring the body's normal anti-tumor immune response
    .
    In recent years, tumor immunotherapy has been highly sought after due to its outstanding efficacy in patients with advanced tumors, huge clinical value and huge market space
    .
    At present, the more concerned tumor immunotherapy is immune checkpoint inhibitors, mainly including CTLA-4, PD-1 and PD-L1
    .
    However, in recent years, as a large number of pharmaceutical companies have entered these popular fields, the track has become more crowded
    .
    Taking PD-1 as an example, due to the difficulty of development, there are countless companies that have deployed PD-1 in recent years.
    According to statistics, CDE has accepted 276 PD-1 mAbs in the first half of 2021 alone, and there are as many as 42 companies applying for PD-1.

    .
    At present, the four domestic monoclonal antibodies, Sindril, Tisleliz, Tripripril and Carrelizon, have been included in the medical insurance through price reduction.
    Many pharmaceutical companies are actively expanding the new indications of PD-1 products, and Many PD-1 products have gone overseas to expand new increments
    .
    As the track becomes more crowded, some pharmaceutical companies have announced the termination of the research and development of this variety of drugs.
    For example, Bio-Thera announced in March 2021 the termination of the clinical trial of BAT1306 (recombinant humanized anti-PD-1 monoclonal antibody injection)
    .
    Judging from the sales data, some PD-1 products are showing signs of decline
    .
    According to Junshi Bio’s 2021 annual report released at the end of March, with its annual revenue increasing by 152% year-on-year, its PD-1 mAb (Toripalimab) revenue fell by 59% to only 412 million yuan
    .
    Under the current fierce competition on the track, developing the next generation of tumor immunotherapy is becoming the goal of some pharmaceutical companies and researchers
    .
    Recently, Zean Biopharmaceuticals announced that it has completed a $17 million Pre-A round of financing led by Xianfeng Qiyun, Qiming Venture Partners and Tigermed
    .
    The funds raised will support the company to further develop technology platforms, build product pipelines, and expand operations teams
    .
    Zean Biomedical is a company dedicated to developing next-generation tumor immunotherapy that activates the immune system and modulates the tumor microenvironment.
    It mainly targets cancer and other complex diseases with clear unmet clinical needs, develops original immunotherapy drugs, and systematically improves patients.
    clinical benefit
    .
    The company has an international team with international vision and rich experience, located in Shenzhen, China, Palo Alto, California, and Heidelberg, Germany
    .
    It is reported that the research and development strategy of Ze’an Biomedicine is to make full use of the company’s three-pronged and mutually synergistic technology platform – reducing immune suppression, reorganizing innate immunity, regulating acquired immunity, and developing technologies that can not only overcome drug resistance and recurrence, but also enhance resistance to New drugs for tumor immunity
    .
    For another example, some researchers are using artificial intelligence (AI) to develop the next generation of tumor immunotherapy
    .
    It is reported that tumors produce a molecule called TGFβ, which has an inhibitory effect on immune checkpoint inhibitors
    .
    In response, scientists at the Johns Hopkins University School of Medicine used AI technology from Insilico Medicine to analyze the pathway of TGFβ and found a hallmark of regulatory T cells, which suppress the immune response and lead to poorer cancer prognosis
    .
    In order to challenge this problem, the researchers invented a bifunctional immunotherapy called Y-trap, and brought two specific Y-trap, targeting CTLA-4/TGFβ and PD-L1/ TGFβ
    .
    Earlier studies have shown that Y-trap, which simultaneously targets CTLA-4/TGFβ, effectively abrogates the effects of regulatory T cells compared to CTLA-4 antibodies alone
    .
    The Y-trap targeting PD-L1/TGFβ is also more effective than the existing PD-L1 antibody in inhibiting tumor growth in the experiment
    .
    These new breakthroughs may have a significant impact on improving the efficacy of tumor immunotherapy
    .
    Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.